Eli Lilly & Co. (LLY) CEO Lechleite Not Concerned About Dividend - CNBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Eli Lilly (LLY) PT Cut to $92 at Leerink Partners
November 23, 2016 2:57 PM ESTLeerink Partners analyst Seamus Fernandez lowered its price target on Eli Lilly (NYSE: LLY) to $92.00 (from $102.00) following the Sola failure but maintains a Outperform rating.
Fernandez commented, "LLY announced that solanezumab did not meet the primary endpoint in the Phase 3 EXPEDITION 3 study. Per our follow up... More
BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
November 23, 2016 1:48 PM ESTBMO Capital downgraded Eli Lilly (NYSE: LLY) from Outperform to Market Perform with a price target of $64.00 (from $91).
Analyst Alex Arfaei commented, "We believe Solas failure in EXPEDITION-3 is clearly a meaningfully negative event as it significantly lowers Lillys long-term growth... More
Eli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - Leerink
November 23, 2016 7:48 AM ESTLeerink Partners analyst Seamus Fernandez weighed in on Eli Lilly & Co. (NYSE: LLY) after sola failed, saying this makes the future of the company's AD portfolio uncertain.
Fernandez commeted, "This morning LLY announced that its EXPEDITION 3 trial of solanezumab (sola) did NOT... More
Eli Lilly & Co. (LLY) Sinks 11% on Solanezumab Failure
November 23, 2016 6:54 AM ESTEli Lilly & Co. (NYSE: LLY) falls 11% after the company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreBiogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure
November 23, 2016 6:52 AM ESTBiogen (NASDAQ: BIIB) is trading down 1% in pre-open trade following news Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreEli Lilly & Co. (LLY) volatility elevated into Alzheimer's data
November 23, 2016 6:51 AM ESTEli Lilly & Co. (NYSE: LLY) November weekly call option implied volatility is at 78, December is at 70, January is at 49; compared to its 52-week range of 14 to 64 into the solanezumab data for Alzheimer's.
... MoreEli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer's Disease Missed Primary Endpoint
November 23, 2016 6:45 AM ESTEli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo (p=.095), as measured by the ADAS-Cog14 (Alzheimer's Disease Assessment Scale-Cognitive subscale).
While the study results, including many secondary clinical endpoints, directionally favored solanezumab, the magnitudes of treatment differences were small.... More
